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background:  The relationship between atrial fibrillation (AF) recurrences & major cardiovascular events is unclear. 
Methods:  We quantitated electrocardiographic burden( “burden”) of recurrent AF in the rhythm control arm of the AFFIRM trial. We 
examined cardiovascular hospitalizations(CVH) & death (D), based on initial antiarrhythmic drug (AAD) selection. Amiodarone (Amio), 
Sotalol (Sot) & Class 1C (flecainide & propafenone) gps were compared to propensity score matched (PSM) Rate gps for freedom from 
CVH or D. AF “burden” at follow up visits was stratified as <25% or >25% of all visits during followup.
results:  687 Amio pts, 581 Sot pts & 251 1C pts from the rhythm arm were matched 1:1 to PSM Rate cohorts. They were comparable for 
baseline characteristics. CVH risk was significantly higher during followup when AF “burden” was >25% compared to < 25% for all 3 AADs 
(Amio Hazard Ratio {HR}= 1.44, p=.001; Sot HR=1.46, p=.0011; Class 1C HR=2.76, p<.0001) (Figure). Mortality for both AF strata for all 3 
AADs was comparable to their matched Rate gps.
Conclusion:  1. While infrequent AF recurrence on AADs used in the AFFIRM trial did not increase risk for CVH or D compared to Rate, 
>25% AF “burden” was associated with substantially increased CVH risk. 2. In AF pts on AADs, total mortality did not differ among the AF 
“burden” strata studied. 3.Quantitation of AF recurrences on AADs may be important in therapeutic decision making to avoid CVH & permit 
earlier institution of alternative rate or rhythm control therapies.
 
